Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta…

Overview of attention for article published in Frontiers in oncology, June 2020

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age and source (51st percentile)

Mentioned by

twitter: 3 X users

Readers on

mendeley: 36 Mendeley

Summary X

So far, Altmetric has seen 5 X posts from 3 X users, with an upper bound of 14,716 followers.

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis https://t.co/oITzJAbKx9

19 Aug 2021

Reply Repost Favourite

30 Mar 2021

Reply Repost Favourite

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line ... https://t.co/oITzJAbKx9

19 Jan 2021

Reply Repost Favourite

RT @FrontOncology: New research: Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as Fi…

01 Aug 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.